| |NOVEMBER 20249US FDA APPROVES PROTEGA PHARMA'S ROXYBONDCHIP ASSISTED BRAIN TUMOR SURGERY TO UNDERGO CLINICAL TRIALSProtega Pharmaceuticals Inc., a unique specialty pharmaceutical company dedicated to ethical pain control and creating new abuse-resistant products, revealed that the US Food and Drug Administration (FDA) has given the green light for Roxybond (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet to be used for treating severe pain that necessitates an opioid analgesic and when other therapies are not effective. Roxybond is the initial and sole FDA-approved abuse-deterrent IR 10 mg oxycodone formulation designed to decrease abuse through intranasal and intravenous methods.Roxybond is developed using SentryBond technology designed to deter abuse. This patented technology mixes non-active components with active pharmaceutical ingredients in order to make it harder to misuse and abuse the tablet, even when it is physically or chemically tampered with. SentryBond is created to uphold the planned release schedule of extended-release (ER) items and postpone the release of IR items."The FDA approval of Roxybond 10 mg with SentryBond is a significant milestone for Protega and fulfills an unmet need for an IR opioid with abuse-deterrent technology that may reduce misuse and abuse while providing pain relief to medically appropriate patients when used as indicated," said Paul Howe, chief commercial officer of Protega. "When manipulated, our innovative technology renders the pill more difficult to misuse or abuse, such as being cut or crushed to snort or inject." POAgraphene-based brain chip is entering its first clinical trial at Salford Royal Hospital, aiming to revolutionize brain tumor surgeries, according to The Guardian. The device, roughly postage-stamp sized, works by detecting cancer cells through differences in electrical emissions between cancerous and healthy brain tissue.Developed by an international research team, the chip utilizes graphene's exceptional conductive properties, which led to a Nobel Prize in Physics in 2010.Professor Kostas Kostarelos, a nanomedicine expert, emphasized that this is the first clinical use of a graphene-based medical device, marking a breakthrough for neural surgery and precision medicine. The chip enhances surgeons' ability to distinguish cancer cells from healthy neurons, particularly in operations near delicate brain areas.Given the 12,700+ annual brain tumor diagnoses in the UK, this advanced technology could improve patient outcomes and research on conditions such as stroke and epilepsy. Researchers consider this a milestone for neural decoding and therapeutic interventions.Salford Royal Hospital in Greater Manchester was managed by Salford Royal NHS Foundation Trust until 2017. Dr Owen Williams serves as the company's CEO. It was declared in December 2017 that the Trust would create a new healthcare entity by merging with Pennine Acute Hospitals NHS Trust. The upcoming institution, known as the Northern Care Alliance NHS Group, is set to have 17,000 employees and a total operating budget of £1.3bn, spanning across Oldham, Bury, Rochdale, Salford, and North Manchester. PO
< Page 8 | Page 10 >